ACADIA Pharma (ACAD) - מקדם מחיר לרווח

The current P/E ratio for ACADIA Pharmaceuticals (ACAD) demonstrates a consolidation phase, where the parameter value reaches 8.60. This trend is supported by patent exclusivity, which protects yields from generics. Stability is ensured by a strong team of neurobiologists incentivized by long-term options. The cash flow is based on the sale of Parkinson's disease treatments through insurance funds and Medicare government programs.
פילוחי מדדים מקיפים ואנליטיקה עבור ACADIA Pharmaceuticals Inc (ACAD)

For ACADIA Pharmaceuticals (ACAD), this ratio reflects the market value of the business relative to its net income, allowing for an assessment of the asset's premium. By analyzing the company's P/E ratio, an investor can compare current capitalization with financial resilience regarding Nuplazid patent disputes and Daybue costs, identifying either an undervalued asset or the risk of inflated expectations amid operating expenses.